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Abstract
Background:  Single-cell assays of immune function are increasingly used to monitor T cell
responses in immunotherapy clinical trials. Standardization and validation of such assays are
therefore important to interpretation of the clinical trial data. Here we assess the levels of intra-
assay, inter-assay, and inter-operator precision, as well as linearity, of CD8+ T cell IFNγ-based
ELISPOT and cytokine flow cytometry (CFC), as well as tetramer assays.
Results: Precision was measured in cryopreserved PBMC with a low, medium, or high response
level to a CMV pp65 peptide or peptide mixture. Intra-assay precision was assessed using 6
replicates per assay; inter-assay precision was assessed by performing 8 assays on different days;
and inter-operator precision was assessed using 3 different operators working on the same day.
Percent CV values ranged from 4% to 133% depending upon the assay and response level. Linearity
was measured by diluting PBMC from a high responder into PBMC from a non-responder, and
yielded R2 values from 0.85 to 0.99 depending upon the assay and antigen.
Conclusion: These data provide target values for precision and linearity of single-cell assays for
those wishing to validate these assays in their own laboratories. They also allow for comparison of
the precision and linearity of ELISPOT, CFC, and tetramer across a range of response levels. There
was a trend toward tetramer assays showing the highest precision, followed closely by CFC, and
then ELISPOT; while all three assays had similar linearity. These findings are contingent upon the
use of optimized protocols for each assay.
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Background
Validation of immunological assays can take a number of
forms, and is required for compliance with Good Labora-
tory Practice (GLP), or for submission of data to licensing
agencies. Two basic components of assay validation are
the demonstration that an assay performs with adequate
reproducibility for the intended purpose, and that the
assay readout is linear over a useful range of data [1].
Specific guidelines exist for validation of traditional
immunoassays such as ELISA, and the expected levels of
precision and linearity of these assays are well-known
[2,3]. Less well-characterized are cellular immunity assays,
of which the single-cell assays like tetramer staining [4],
cytokine flow cytometry (CFC) [5,6], and ELISPOT [7] are
among the most popular. Some data has been published
regarding the precision of individual assays [8-10], and
there is very limited data on the linearity of CFC [11].
However, precision and linearity have not been compared
across assays, and expected levels of precision and linear-
ity of these assays have not been determined in a side-by-
side fashion.
Precision and linearity are important aspects of cellular
immunity assays, since (a) cellular assays are inherently
more complex, and thus less reproducible, than tradi-
tional immunoassays; and (b) cellular immunity assays
are frequently used to detect rare antigen-specific T cell
populations, which may be present at or near the assay
detection limit. It is thus crucial to demonstrate that an
assay is reproducible enough to generate reliable data in
the response range expected for, say, a vaccine clinical
trial, and that linearity is adequate to quantitatively com-
pare results between treatment groups or between trials.
Fortunately, we now know that at least some vaccines to
HIV and cancer, for example, can generate readily detect-
able T cell responses by assays such as tetramer, CFC, and
ELISPOT [12,13]. Still, there is wide variability in the per-
formance of such assays between labs [14]. Compliance
with GLP thus requires that a given lab demonstrate its
proficiency for a given assay, preferably with reference to
an accepted standard.
Here we compare results from optimized protocols for
tetramer staining, CFC, and ELISPOT, performed on
shared cryopreserved PBMC specimens, with expert labo-
ratories performing the individual assays. From this data,
we derive target values for those who wish to determine
precision and linearity of these assays in their own labora-
tory, and we also facilitate comparison of the three assays
with regard to their relative precision and linearity.
Results
Study design and response levels of donors
In order to allow meaningful comparisons between
assays, this study was performed using a format previously
published [15], in which three laboratories, each expert at
an individual assay, performed their assay of expertise in
parallel on the same cryopreserved PBMC. PBMC from
healthy CMV seropositive donors were chosen to repre-
sent a high, medium, and low responder to CMV
pp65495–503 peptide [16] and/or a CMV pp65 peptide mix
[17]. Actual mean responses across all the assays as
obtained in this study are shown in Table 1. Assays were
performed with six replicates in order to determine intra-
assay precision. They were repeated on eight different days
in order to determine inter-assay precision. Three opera-
tors performed assays in parallel on a single day in order
to determine inter-operator precision. And triplicate sam-
ples from the high responder were serially diluted into
non-responsive PBMC in order to determine linearity.
Results were then collated across the three laboratories.
Precision of individual assays
When the coefficient of variation (CV) of six parallel rep-
licates was plotted against the mean response level, a char-
acteristic non-linear relationship was observed for all
three assays (Figure 1), whereby the CV rose dramatically
as the mean approached zero. Since the six replicates were
performed on eight separate days, a standard deviation
(SD) could be determined for the intra-assay CV. Taking
the mean+SD of the intra-assay CV at any given response
level allows one to determine an "acceptable zone"
wherein a laboratory validating these assays might expect
their data to lie (gray zone in Figure 1). For example, at a
response level of 0.25%, one would expect a CV no higher
Table 1: Mean response levels of the three CMV-responsive donors
% CD3+CD8+ cells ELISPOT (peptide 
mix)
CFC (peptide mix) CFC (pp65495–503)T e t r a m e r  
(pp65495–503)
ELISPOT 
(pp65495–503)
Donor 41 (low) 20.3% 270 SFC1 [0.53%] nd2 0.06%2 0.06%2 8 SFC1 [0.02%]
Donor 68 (med) 12.1% 285 SFC1 [0.94%] 0.28%2 0.28%2 0.25%2 31 SFC1 [0.10%]
Donor 43 (high) 26.3% 95 SFC1 [0.14%] 0.87%2 0.93%2 1.27%2 28 SFC1 [0.04%]
1 ELISPOT results reported as SFC per 2.5 × 105 PBMC. Numbers in brackets indicate the values when re-calculated as % of CD8+ T cells. Note that 
ELISPOT responses with peptide mix did not match the other assays in terms of low, medium, and high responders.
2 CFC and tetramer results reported as % of CD8+ T cells. nd = CFC was not done on this donor due to predicted very low response (0.02%) seen 
in pre-screening.BMC Immunology 2008, 9:9 http://www.biomedcentral.com/1471-2172/9/9
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than about 0.15 (15%) for either tetramer or CFC, based
on these data. Similarly, for a response level of about 30
SFC in ELISPOT, one would expect a CV no higher than
about 0.60 (60%).
Because antigen-specific assays are often used to analyze
data in a range where CV is non-linear with the mean, we
chose to use SD as a measure of variability in further anal-
yses. As shown in Figure 2, the SD was relatively linear
with mean for all three assays, when comparing six paral-
lel replicates (intra-assay precision, left panels), or eight
separate experiments (inter-assay precision, middle pan-
els), or three different operators (inter-operator precision,
right panels). For ELISPOT, the SD was significantly lower
for intra-assay precision compared to inter-assay (p =
0.03) and inter-operator (p = 0.03) precision. There was a
similar trend for CFC, though the comparisons did not
reach statistical significance (p = 0.06). Tetramer assays
had low SD in all three situations, with no significant dif-
ferences among intra-assay, inter-assay, and inter-opera-
tor precision (0.25 < p < 0.75).
Comparative precision of the three assays
In Figure 2, it is difficult to compare the precision across
all three assays, because the readout for ELISPOT (SFC per
2.5 × 105 PBMC) is different than the readout for CFC and
tetramer staining (percent of CD8+ T cells). In order to
compare all three assays on the same scale, the ELISPOT
values were converted to a percent scale (since the percent-
age of CD8+ T cells in each PBMC sample was known).
The result (Figure 3) allows visual comparison of the pre-
cision between assays. For all three conditions (intra-
assay, inter-assay, and inter-operator precision), ELISPOT
tended to have higher SD than CFC or tetramer. This trend
was greatest for inter-assay and inter-operator studies.
Linearity
Figure 4 shows the results of linearity studies, in which
PBMC from a CMV-responder (donor 43) were diluted
into PBMC from a known CMV non-responder. This
design was chosen to mimic physiological conditions of
donors with few responsive cells in the context of many
non-responsive cells. It was also possible to take this
approach, since allogeneic responses were not detected
using this particular donor pair, stimulation time, and
cytokine readout (i.e., backgrounds were as low as those
seen in precision experiments with the CMV-positive
donor alone). All three assays showed highly significant
linearity (p < 0.0001). For the pp65495–503 peptide system,
CFC and tetramer showed almost identical R2 values (R2 =
0.99), while ELISPOT was lower (R2 = 0.85). This could
relate to the relatively low pp65495–503 response of the
chosen donor in ELISPOT versus the other two assays. For
the pp65 peptide mix system, where the ELISPOT
response of this donor was higher, ELISPOT and CFC
showed similar R2 values (0.97–0.98).
Discussion
A number of studies have been published comparing
ELISPOT, CFC, and tetramer staining [15,18-27]. How-
Intra-assay CVs Figure 1
Intra-assay CVs. The mean CV for six replicates was plotted for samples from three donors and two different antigen stimu-
lations in tetramer, CFC, and ELISPOT assays. Circles represent donor 41; triangles, donor 68; and squares, donor 43. Open 
symbols represent CMV pp65495–503 responses; closed symbols represent CMV pp65 peptide mix responses (CFC and ELIS-
POT assays only). Note that certain responses were very similar, so some symbols overlap. Error bars represent the SD of 10 
times that the six replicates were repeated. The gray zones indicate the area within which a laboratory doing validation could 
expect their data to lie.
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ever, while these studies have addressed issues such as rel-
ative sensitivity of the assays, direct comparisons of
precision and linearity have not been done. The best pre-
vious assessments of inter-laboratory precision came from
standardization studies carried out for ELISPOT [14,28] or
CFC [10]. The present study was designed to compare
these assays with regard to precision and linearity, and in
so doing, to provide target values for laboratories wishing
to validate their own protocols for any of these assays. It
should be noted that these targets may be specific to IFNγ
and to the antigen systems used (CMV pp65495–503 and
pp65 peptde mix), and can not necessarily be generalized
to other cytokines and antigens.
In comparing assays, the choice of protocol is crucial; one
wishes to compare fully-optimized versions of each assay.
As such, we chose individual labs recognized as experts in
each type of assay (tetramer, CFC, and ELISPOT) and
allowed them each to use their own optimized protocol.
In the case of ELISPOT, this protocol did not use costimu-
latory antibodies, while in CFC it did. Validation data in
the lab doing ELISPOT showed that inclusion of costimu-
latory antibodies was not warranted based on increased
backgrounds (data not shown); while similar data in the
CFC lab supported the use of costimulation. The net
result, that the assays might not give quantitatively equiv-
alent results, was accepted in favour of the idea that each
SD of each assay Figure 2
SD of each assay. The mean response for each sample (as per Figure 1) was plotted versus the SD of six replicates (intra-
assay precision), eight assays on different days (inter-assay precision), or three operators on the same day (inter-operator pre-
cision). Circles represent donor 41; triangles, donor 68; and squares, donor 43. Open symbols represent CMV pp65495–503 
responses; closed symbols represent CMV pp65 peptide mix responses (CFC and ELISPOT assays only). Error bars in the 
intra-assay graphs represent the SD of 10 times that the six replicates were repeated. Lines represent linear regression of the 
combined data (both antigens, where used), with 95% confidence intervals of the regression shown with dotted lines.
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assay was optimally configured for its own best perform-
ance.
Often, CV has been used as a measure of precision that is
independent of the units in which data is expressed (e.g.,
SFC or percent positive cells) [29]. However, the stability
of the CV deteriorates at very low means (Figure 1), so it
is difficult to use it as a robust measurement of precision
for low-level responses. Since antigen-specific assays are
often used to assess very low response values, we chose
instead to focus on SD, which we found to be highly linear
with the response mean (Figure 2).
In general, there was a trend toward higher precision in
intra-assay measurements compared to inter-assay or
inter-operator measurements, in agreement with a previ-
ous study on CFC [11]. Since the inter-assay and inter-
operator precision studies were not repeated multiple
times, we could not derive statistical tolerances around
the SD values in Figure 2. However, a laboratory wishing
to validate these assays could use this figure as a guide,
comparing their own internal validation data to the figure
for any given response level.
In order to compare precision across all three assays, ELIS-
POT values were converted to the same scale as CFC and
tetramer staining (Figure 3), and the SD was plotted ver-
sus mean. Deriving a regression line through this data for
each assay, we observed that ELISPOT SD tended to be
higher, for any given response level, than CFC or tetramer
SD. While we did not validate this trend statistically, it is
concordant with previous studies that reported relatively
low inter-laboratory precision for ELISPOT [14] and rela-
tively high inter-laboratory precision for CFC [10], at least
when data were analyzed centrally.
Why would ELISPOT assays have poorer precision in this
study? One relevant factor could be the number of cells
collected per data point, since assay precision is depend-
ent upon counting statistics. The ELISPOT assay was opti-
mized such that 2 × 105 PBMC per well gave the highest
counting efficiency. CFC assays collected 40,000
CD3+CD8+ cells per sample, and tetramer assays collected
30,000 CD8+ T cells. Assuming CD3+CD8+ cells to be
about 15% of PBMC, this means that roughly 30,000
CD3+CD8+ cells were present in each ELISPOT well. While
the difference relative to CFC (30,000 versus 40,000)
could explain some difference in precision, it is unlikely to
be a major factor, at least at the higher response levels
tested.
Another factor in ELISPOT assays is the fact that precision
is dependent upon cell counting and pipetting. All calcu-
lation is based upon the assumption that 2 × 105 PBMC
were in fact plated in every well. If the original PBMC
count were in error, this would introduce a systematic bias
in that assay's results that would potentially affect inter-
assay or inter-operator reproducibility. And if pipetting
were not precise, intra-assay reproducibility would be
affected as well. In contrast, tetramer and CFC assays have
a percentage readout that is less dependent upon the true
number of cells plated per sample.
Comparison of precision across assays Figure 3
Comparison of precision across assays. ELISPOT means and SD for each sample were converted to percent of CD8+ T 
cells using the formula SFC/2.5 × 105/(CD8 percent of PBMC for that donor)×100. This allowed SD to be compared on the 
same scale. Note that the regression line for ELISPOT (dotted) is consistently higher than the regression line for CFC (dashed) 
or tetramer (solid). Due to complexity, data points for different donors and different antigens are not distinguished in this Fig-
ure; please refer to Figure 2 for relative responses of individual donors and antigens.
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The ELISPOT assay is also unique in that it is a monolayer
assay, and cell stimulation could be limited by the ability
of T cells and APC to interact when they are spread out
over a filter-bottom well. This could affect the reproduci-
bility of stimulation, and could also explain undercount-
ing of responsive T cells in ELISPOT relative to CFC. Lack
of costimulatory antibodies in the ELISPOT assay, which
were used in CFC, could also cause undercounting. Fnally,
undercounting could result from coincident spots or
other imprecisions in the computer-aided ELISPOT
counting system. We saw such undercounting to a varia-
ble degree in this study, when ELISPOT results were con-
verted to the same scale as CFC and tetramer results (see
Table 1). ELISPOT has been shown in other studies to
undercount positive events by 4- to 10-fold relative to
CFC or tetramer staining [23,24], even in the same CMV
system used for the current study [15]. Thus, the ELISPOT
regression line for SD versus mean (Figure 3) could be
expected to shift leftward relative to CFC and tetramer, if
SD for a given sample were actually equal between the
three assays.
For all the above reasons, it is not surprising that ELISPOT
precision was not as high as CFC and tetramer. In fact,
common practice in the field takes this into account, in
that ELISPOT assays are typically done with 3–6 replicates
per sample, while this is rarely done in CFC and tetramer
assays. It was only for purposes of fair comparison that a
single well was considered as one data point in this study.
With regard to linearity, we used a dilution methodology
in which responder PBMC were diluted into non-
responder PBMC. There was the potential for confound-
ing artifacts with this method, including the possibility of
loss of relevant antigen-presenting cells with serial dilu-
tion, and the possibility of allogeneic responses. Fortu-
Linearity of assays Figure 4
Linearity of assays. Triplicate samples of PBMC from a HLA-A2+ high-responding donor (#43) were serially diluted into 
PBMC from a known HLA-A2+ non-responder. The same non-responding donor was used for all assays. Unstimulated back-
ground was subtracted for each dilution point in CFC and ELISPOT assays. This background was uniformly low (< 0.08% for 
CFC and < 15 SFC per 2.5 × 105 PBMC for ELISPOT) despite the used of allogeneic PBMC for the dilution. Note that the 
pp65495–503 peptide response of this donor (#43) was much lower in ELISPOT compared to the other two assays.
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nately, these were not observed as significant factors.
Linearity of CFC and ELISPOT were similar to tetramer,
except in the instance where ELISPOT response was dis-
proportionately low compared to the CFC or tetramer
response. This suggests that antigen-presenting cell fre-
quency was not a major limiting factor. In terms of alloge-
neic responses, unstimulated CFC background at each
dilution was 0–0.07% of CD8+ T cells, which was not dif-
ferent from background in the assays that did not contain
allogeneic cells. For ELISPOT, the average background in
the linearity studies was 4.7 SFC per 2.5 × 105 PBMC, com-
pared to 5.0 SFC when donor 43 (high responder) PBMC
were tested alone.
In terms of assay comparison, it is worth noting that the
ELISPOT assay does not easily allow for phenotyping of
responsive cells as CD4+ or CD8+, etc. In our study, we for-
tuitously chose donors whose pp65 peptide mix
responses were almost entirely CD8-restricted
(pp65495–503 peptide responses should be CD8-restricted
by nature). We thus focused on CD8+ T cell responses for
all CFC assays. However, when using either CMV
pp65495–503 or peptide mix stimulation, we observed that
the rank order of donors was different for ELISPOT com-
pared to the other two assays. CD4 responses in CFC were
0.2–0.4% for all donors (data not shown), so this was not
sufficient to account for the difference. One outcome of
this anomaly is that the pp65495–503 linearity data for ELIS-
POT was generated with a donor whose ELISPOT
response was many fold lower than that donor's CFC or
tetramer response. We thus focused more attention on the
pp65 peptide mix ELISPOT response, which was at least
somewhat higher, and which showed comparable linear-
ity to CFC and tetramer.
Tetramer staining is by far the simplest of the three assays,
requiring only phenotypic staining of PBMC. It is there-
fore not unexpected that it would have the highest preci-
sion, as the complexity of activation and sample
processing should negatively impact precision of CFC and
ELISPOT. However, it is interesting that CFC precision
and linearity were not much different from that of
tetramer staining. This is consistent with the notion that
precision of CFC assays is largely related to gating and
analysis, rather than activation or processing variables
[10].
Although our focus in this paper is on precision and line-
arity, a limit of detection for each assay can also be deter-
mined from our data. This limit could be defined, for
example, as 2 SD above the mean of replicate negative
control samples. Such a limit is of course dependent upon
the number of events collected, as previously described
for CFC [30], as well as the negative control background,
which varies between donors. In our study, we calculated
an average lower limit of detection of 0.08% for CD8+ T
cell IFNγ production in CFC, and 64 SFC per 2.5 × 105
PBMC in IFNγ ELISPOT. Note that these detection limits
were the average across three donors, and were lower for
those donors with low background. A similar calculation
could not be done for tetramer staining, because a nega-
tive control (irrelevant tetramer) was not used.
Conclusion
From this comparison study, we provide target values for
precision and linearity of tetramer, CFC, and ELISPOT
assays, using cryopreserved PBMC. We conclude that all
three assays can be performed with reasonable precision
and linearity. Intra-assay precision was generally lower
than inter-assay or inter-operator precision. Tetramer
staining tended to have the highest precision and linear-
ity, followed closely by CFC and then ELISPOT.
Methods
Donors and CMV responses
Three HLA-A2+, CMV seropositive healthy subjects were
chosen from previous work, which suggested that they
represented low (~0.1% tetramer+ or IFNγ+ cells, or ~30
SFC per 2.5 × 105 PBMC), medium (~0.3% tetramer+ or
IFNγ+ cells, or ~100 SFC per 2.5 × 105 PBMC), and high
(~1% tetramer+ or IFNγ+ cells, or ~200 SFC per 2.5 × 105
PBMC) responders to CMV pp65495–503 peptide. Actual
mean values obtained in this study are shown in Table 1.
Collection and cryopreservation of PBMC
PBMC from leukapheresis were isolated using Ficoll gradi-
ent separation as previously described [15]. To cryopre-
serve PBMC, 2× freezing media was first prepared,
containing 20% DMSO in RPMI (Sigma Chemical Co., St.
Louis, MO) containing 12.5% human serum albumin
(HSA) (Gemini Bioproducts, Woodland, CA), and cooled
on ice for a minimum of 30 minutes. Ficolled PBMC at 2
× 107 viable lymphocytes/ml were resuspended in cold
RPMI+12.5% HSA with no DMSO. An equal volume of
chilled 2× freezing media was added to the cell suspen-
sion dropwise, while gently swirling the tube. One ml of
this cell suspension was aliquoted into each cryovial
(Sarstedt, Inc., Newton, NC). Once aliquoted, cryovials
were placed on ice and then transferred into a freezing
container (Nalgene, Rochester, NY), and stored at -80°C
for 24 hours. Cryovials were then transferred into liquid
nitrogen for long-term storage. After 30 days, cryovials
were overnight shipped on dry ice to the recipient labora-
tories.
Thawing
Cryopreserved PBMC were stored at -80°C until thawing
to set up the assays. Cryopreserved cells were thawed and
slowly diluted with 8 ml of warm RPMI+10% fetal bovine
serum+antibiotics (cRPMI-10, all components fromBMC Immunology 2008, 9:9 http://www.biomedcentral.com/1471-2172/9/9
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Sigma). The cells were centrifuged for 7 minutes at 250 ×
G, then resuspended as described below for each assay.
Viability and recovery were checked using Trypan blue,
and were > 80% and > 50%, respectively, in all samples.
Antigens
A common source of peptide antigens was shared among
laboratories for CFC and ELISPOT assays. These included
CMV pp65 peptide mix (BD Biosciences, San Jose, CA;
used at a final concentration of 1.7 μg/ml/peptide); and
CMV pp65495–503 peptide (SynPep Corp., Dublin, CA;
used at a final concentration of 10 μg/ml).
Tetramer assays
Staining was done using the Multiple Antibody Single
Color protocol (iMASC, Beckman Coulter Inc., Fullerton,
CA) as previously described [15]. Briefly, PBMC were
resuspended at 1 × 107 per mL in HBSS+0.1% bovine
serum albumin+0.02% sodium azide. 100 μL of PBMC
per sample were stained for 30 minutes at room tempera-
ture using CD8 FITC, HLA-A2 tetramer loaded with CMV
pp65495–503 PE, and CD4, CD13, and CD19 PE-Cy5 (all
from Beckman Coulter). Samples were washed and ana-
lyzed on a FACS Calibur flow cytometer (BD Biosciences).
30,000 CD8+  T cells were collected, and results were
reported as the percentage of CD8+, PE-Cy5-negative cells
that were tetramer-positive. No correction for background
staining with irrelevant tetramer was used, but the test
tetramer showed undetectable staining on CMV-negative
donors (not shown).
CFC assays
Activation and processing were done as previously
described [15]. Briefly, PBMC were resuspended at 1 × 107
per mL in cRPMI-10, and 200 μL were plated per well in
96-well round-bottom plates. After overnight rest at 37°C,
activation reagents (stimulus+brefeldin A+costimulatory
antibodies to CD28 and CD49d) were added and the cells
incubated at 37°C for 6 hours. The cells were then fixed
and permeabilized as per reference [15], followed by
staining with IFNγ FITC/CD69 PE/CD8 PerCPCy5.5/CD3
APC (BD Biosciences) for 1 hour at room temperature in
dark. Plates were washed and cells resuspended in 1%
paraformaldehyde in PBS, then acquired on a FACSCali-
bur flow cytometer (BD Biosciences). 40,000 CD3+CD8+
lymphocytes were collected per sample. Data were
reported as the net percent of CD3+CD8+lymphocytes that
were CD69+IFNγ+ after subtracting the average response of
unstimulated samples.
ELISPOT assays
Activation and processing were done largely as previously
described [15]. Briefly, Multiscreen-HA 96-well plates
(Millipore, Bedford, MA) were coated with mouse anti-
human IFNγ mAb, and the plates washed and blocked as
per the referenced publication. PBMC were resusupended
at 1 × 106 per mL, and 200 μL plated per well along with
the appropriate antigen. Stimulation was for 18–24 hours
at 37°C in 5% CO2. Plates were washed and developed as
in reference [15], and the number of spots per well was
determined using a KS ELISPOT Automated Reader Sys-
tem with KS ELISPOT 4.2 Software (Carl Zeiss, Inc.,
Thornwood, NY). SFC per 2.5 × 105 PBMC were reported
after subtracting the average response of unstimulated
samples.
Design of precision and linearity studies
Data for each assay were acquired on a single instrument,
using the same settings throughout the study. For flow
cytometry-based assays, an optimized gating template and
instrument settings file were used throughout the study,
including inter-operator precision studies. All data for lin-
earity, intra-assay, and inter-assay precision were per-
formed by a single operator. For conversion of ELISPOT
data to percent of CD3+CD8+  cells, the percent of
CD3+CD8+ cells was determined from a representative
subset of the CFC data, and was found to be very consist-
ent across days and across operators. However, it varied
significantly from one donor to the next (see Table 1). The
ELISPOT data was converted to percent response as fol-
lows: SFC/2.5 × 105/(mean CD3+CD8+ percent for that
donor)×100.
Statistical analyses
For comparison of SD among samples in intra-assay ver-
sus inter-assay or inter-operator studies, a Wilcoxon
Matched Pairs test was used. Statistical analyses were car-
ried out in GraphPad Prism software (San Diego, CA).
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